KMCRIC

Nanotechnology offers exciting opportunities in the fight against cancer. New technological breakthroughs have enabled innovative therapeutic applications of nanoparticles and have facilitated diagnostics at the nanoscale.

As examples, the delivery of RNA with nanoparticles (in the product patisiran), has been approved by EMA/FDA in 2018, while the first liquid biopsy for prostate cancer based on exosome analysis was launched in 2016.

This conference aims to bridge nanotechnology with clinical and pre-clinical cancer research, and to highlight recent applications in patient care. It will provide an overview of the latest developments in the field of cancer-related nanotechnologies. There will be many opportunities to present work, with lively poster sessions and eight proffered papers selected from submitted abstracts.